Reproducibility of multiparametric kidney MRI on 1.5T scanners
Official title: Reproducibility of Multiparametric Renal Magnetic Resonance Imaging on 1.5T MRI Scanners (RESPECT_1.5T Sub-study)
Run by Mario Negri Institute for Pharmacological Research · NCT06884410 · Data updated 2026-11-12
This project will test how consistently multiparametric kidney MRI measurements can be obtained on common 1.5T MRI scanners in healthy adults aged 18–70.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 48 (estimated) |
| Sponsor | Mario Negri Institute for Pharmacological Research Academic / other |
| Locations | 4 sites (Aarhus and 3 other locations) |
| Status | Recruiting |
| Started | April 12, 2025 |
| Main results expected | April 2026 |
| Study ends | April 2026 |
| Registry record updated | September 2, 2025 |
| Trial ID | NCT06884410 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are healthy men and women aged 18–70 with normal blood pressure, normal kidney function (eGFR ≥60 mL/min/1.73 m2), negative urine tests for blood/protein, no ongoing medical therapy, and no MRI contraindications.
✕Probably not a fit
People with chronic kidney disease, active medical treatments (e.g., for diabetes or dyslipidemia), past or current cancer, pregnancy, or MRI-incompatible implants will not qualify and are unlikely to receive direct clinical benefit from this imaging reproducibility study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multicenter prospective study enrolls healthy volunteers to measure how reproducible multiparametric renal MRI metrics are when acquired on 1.5T scanners using standardized acquisition and processing protocols. Participants will undergo repeated MRI scans at participating sites to quantify within- and between-scanner variability and to compare reproducibility across sex and age groups. A subgroup of participants already enrolled in the RESPECT trial will permit direct comparison of reproducibility between 1.5T and 3T field strengths. The study aims to inform harmonized protocols and normative benchmarks to support wider clinical use of renal MRI.
Why it matters
Potential benefit: If successful, this work could enable reliable kidney MRI measures on widely available 1.5T scanners, helping earlier detection and more consistent monitoring of kidney disease in more clinical centers.
How similar studies have gone: Previous multicenter work—most notably the RESPECT trial—has shown repeatability of multiparametric renal MRI at 3T, but reproducibility on commonly used 1.5T scanners has been less well studied.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Provision of written informed consent prior to any study specific procedures * Male and female subjects aged \[18-70\] years * Office SBP values \< 140 mmHg and DBP values ≤ 90 mmHg, under no antihypertensive therapy * Normal renal function defined as: estimated glomerular filtration rate \[eGFR\] ≥ 60mL/min/1.73m2 (using CKD-EPI Creatinine Equation) * Negative result upon urine testing for haematuria or proteinuria. Exclusion Criteria: * Previous enrollment in the present substudy * Contraindications to MRI including caustrophobia, pregnancy, cardiac pacemakers or other MRI-incompatible prostheses * Ongoing therapy (e.g. for diabetes, dyslipidemia, or any acute disease) * Past or current oncological pathology
Where it's running
-
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Bo, Italy Recruiting -
Aarhus University Hospital
Aarhus, Denmark Not yet recruiting -
University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University
Mannheim, Germany Not yet recruiting -
Clínica Universidad de Navarra
Pamplona, Navarre, Spain Not yet recruiting
Study contacts
- Principal investigator: Giuseppe Remuzzi, M.D. — Istituto Di Ricerche Farmacologiche Mario Negri
- Study coordinator: Matias Trillini, M.D.
- Email: matias.trillini@marionegri.it
- Phone: +390354535411
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using PSMA PET to improve detection of significant prostate cancer lesions during MRI-targeted biopsy
This study is testing if a special type of imaging called PSMA PET can help find important prostate cancer spots that might be missed during regular MRI-targeted biopsies in men with high-risk localized prostate cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.